Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements may ...

Lenacapavir has delivered impressive trial results and, in July, it received official backing from the World Health ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Two partnerships will provide millions of people access to what is widely described as the most effective HIV prevention drug ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The Gates Foundation CEO Mark Suzman on Wednesday warned that child mortality is at risk of rising this year for the first ...

Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year.

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with ...

A new and low cost HIV prevention jab, Lenacapavir is considered a medical breakthrough, offering a promising hope to end global epidemic. A twice-yearly and cost-effective HIV prevention jab ...

A new HIV prevention drug, Lenacapavir, will be made available at a significantly reduced cost in over 100 low-income countries by 2027.

Global health groups will provide backing for two generic manufacturers to produce and distribute a low-cost version of a new HIV prevention drug in poor countries.